

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

INCLUSION OF “TENOFIVIR AMIBUFENAMIDE TABLET” IN THE NATIONAL REIMBURSEMENT DRUG LIST

This announcement is made by Hansoh Pharmaceutical Group Company Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce that “Tenofovir Amibufenamide Tablet” (product name: HENGMU 恒沐®, the “**Product**”), an innovative drug self-developed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (江蘇豪森藥業集團有限公司), a subsidiary of the Company, has been included into the updated Catalogue of National Reimbursement Drug List (the “**NRDL**”) issued by the China National Healthcare Security Administration.

The Product has been granted drug registration approval by National Medical Products Administration of the People’s Republic of China in June 2021, and is an anti-infective drug indicated for the treatment of chronic hepatitis B virus infection in adults.

The inclusion of the Product into the updated NRDL will help the Group to further enhance the affordability and accessibility of the Product among patients.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, December 3, 2021

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.